R21/Matrix-M in African Children Against Clinical Malaria

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

4,800

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

March 21, 2023

Study Completion Date

September 30, 2027

Conditions
Malaria
Interventions
BIOLOGICAL

R21/Matrix-M

Adjuvanted malaria vaccine

BIOLOGICAL

Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine

Placebo Comparator

Trial Locations (1)

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

All Listed Sponsors
collaborator

Institut de Recherche en Sciences de la Sante, Burkina Faso

OTHER_GOV

collaborator

Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest

OTHER_GOV

collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

KEMRI-Wellcome Trust Collaborative Research Program

OTHER

collaborator

Ifakara Health Institute Clinical Trial Facility, Bagamoyo Research and Training Centre, PO Box 74, Bagamoyo, Tanzania

UNKNOWN

collaborator

London School of Hygiene and Tropical Medicine

OTHER

lead

University of Oxford

OTHER